New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons

Lucia Wang,^{†,§} Valeria S. Guillen,^{‡,§} Naina Sharma,[‡] Kevin Flessa,[†] Jian Min,[‡] Kathryn E. Carlson,[‡] Weiyi Toy,^{||} Sara Braqi,[†] Benita S. Katzenellenbogen,[‡] John A. Katzenellenbogen,^{‡,||} Sarat Chandarlapaty,^{||} and Abhishek Sharma^{*,†,||}

[†]Department of Chemistry and Chemical Biology, Stevens Institute of Technology, Hoboken, New Jersey 07601 United States

[‡]Department of Chemistry, Department of Molecular and Integrative Physiology, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801 United States

^{||}Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States

S Supporting Information

ABSTRACT: An effective endocrine therapy for breast cancer is to selectively and effectively degrade the estrogen receptor (ER). Up until now, there have been largely only two molecular scaffolds capable of doing this. In this study, we have developed new classes of scaffolds that possess selective estrogen receptor degrader (SERD) and ER antagonistic properties. These novel SERDs potentially inhibit MCF-7 breast cancer cell proliferation and the expression of ER target genes, and their efficacy is comparable to Fulvestrant. Unlike Fulvestrant, the modular protein-targeted chimera (PROTAC)-type design of these novel SERDs should allow easy diversification into a library of analogs to further fine-tune their pharmacokinetic properties including oral availability. This work also expands the pool of currently available PROTAC-type scaffolds that could be beneficial for targeted degradation of various other therapeutically important proteins.

KEYWORDS: Targeted protein degradation, estrogen receptor, antiproliferation, breast cancer, antagonist

Estrogen receptor- α (ER α) is the target of endocrine therapies for treatment of the more than 70% of breast cancers that are ER-positive.¹ Among these therapies, small-molecule-induced, targeted degradation of ERs is the last line of treatment, especially in metastatic breast cancer patients who have become resistant to therapies that inhibit the function of ER.² This targeted destruction of ER is induced by molecules (selective estrogen receptor degraders, SERDs) that possess distinct structural elements for binding to the ligand-binding pocket (LBP) of ER and recruitment of the cellular protein degradation machinery. Despite the immense therapeutic importance of SERDs, the repertoire of molecular scaffolds known to induce ER degradation (degrons) has been rather limited, and their degron properties were discovered serendipitously. Currently, there is only one clinically approved SERD, Fulvestrant³ (Figure 1a), and some related analogs⁴ that possess a core for binding in the LBP and a long alkyl side chain (degron) that induces ER degradation.³ The clinical utility of Fulvestrant is hampered due to its poor oral bioavailability, so that it has to be administered as a large painful intramuscular injection.⁵ Moreover, the bulky and steroidal structure of Fulvestrant also limits further chemical diversification to improve its bioactivity. A second structurally distinct small molecule scaffold/degron known to confer SERD properties is

an acrylic acid based side chain, which was first developed in 1994 (GW5638, Figure 1b),⁶ as well as more recent versions having diversified ligand core elements but the same side chain; this class of SERDs is still awaiting full clinical evaluation.^{7–10}

In view of the extremely limited pool of currently available SERDs,¹¹ there is an urgent need for development of structurally novel classes of small molecules that are not only capable of inducing ER degradation in breast cancer and blocking cancer cell proliferation, but also ideally would allow easy chemical diversification to fine-tune their physicochemical and biological properties.

Recently, there has been an increased interest in developing targeted protein degradation strategies for the treatment of various types of cancers and other diseases.^{12–16} These proteolysis targeting chimeras (PROTACs) possess a targeting ligand attached to a recognition motif (“degron”) that binds to E3 ubiquitin ligases or other proteins that ultimately promote ubiquitination-dependent proteasomal degradation of the target protein. In this context, several interesting and useful “degron motifs” have been developed for the targeted destruction of

Received: March 5, 2018

Accepted: July 5, 2018

Published: July 5, 2018

Figure 1. (a,b) Previously known SERD scaffolds and (c) the newly developed class of SERDs. The number in parentheses represents the year of discovery of each SERD. The big time gap between the last discovered SERD (b) and the latest (c) illustrates the challenges in discovering new SERD scaffolds.

clinically relevant proteins.^{12,13,17} The previous PROTACs for ER comprised peptidic¹⁷ or bestatin ester-based degrons,^{18,19} which limited their drug-like properties or imparted off-target effects and low potency, besides requiring specific E3 ligases for ubiquitin-mediated degradation.^{17,20} In order to realize the full potential of PROTACs as a therapeutic option for breast cancer and other diseases, it would be beneficial to develop novel and simpler degrons that allow the characterization and optimization of functional contributions made by distinct regions of a degron to ultimately aid its clinical application.

Nature devised the ubiquitin-dependent degradation pathway for removing unwanted or damaged cellular proteins. An important component of this protein quality control machinery is the N-end rule pathway, wherein the N-terminus of target proteins is conjugated with a destabilizing amino acid (degron) that is recognized by the ubiquitin proteasome system.²¹ In the course of our efforts to develop novel ER antagonists/SERDs,^{22,23} we became interested in exploring the selective degradation of ERs using ligands that carry a destabilizing N-end rule amino acid or other degrons. Herein, we report on a novel class of PROTACs (Figure 1c) that (i) effectively induce ER degradation and show potent antiproliferative activity; (ii) can be easily diversified to fine-tune their biological/ADMET properties, and (iii) significantly expand the repertoire of currently known PROTAC scaffolds.

Our molecular design for SERDs involved a bisphenolic-adamantyl system (Scheme 1) as the “core” to anchor our ligand inside the LBP of ER. We had earlier developed these cyclic cores as very high affinity ligands (ca. 2–3 times higher affinity than estradiol) for ER.²⁴ Our molecular modeling studies (Figure S2 and S3) suggested that one of the phenols of these ligands forms the canonical H-bonds with Glu353 and Arg394 in ER α , while a side chain attached on the other phenol is expected to be projected outside the surface of ER through an exit channel in the antagonist conformation of the ligand-binding domain. Thus, we used this second phenol to attach an alkyl linker possessing an amine terminus for coupling with various degron candidates.

We initially selected Leu, Phe, and Trp from the pool of amino acids that are known to participate in the N-end rule pathway.²¹

Scheme 1. Divergent Route for Synthesis of Novel SERDs; (inset) Our Model for Design of ER Targeting PROTACs

This selection was based on the assumption that mild to strong hydrophobicity might also contribute to their degron action on ER, as is the case with other SERDs. In view of the easy availability of Boc-amino acids and the hydrophobic character of Boc group,²⁵ these N-protected (L) amino acids were chosen as degron-type elements along with their unprotected versions for comparison. These amino acids were converted into their NHS esters and then coupled to the amine side chain of ER ligands to give compounds 2–4 (Scheme 1, Table 1).

Binding assays showed that installation of these three degron side chains on this ligand core did not preclude them from binding directly to ER (Table 1), although their relative binding affinities (RBAs) decreased somewhat from that of the parent bisphenolic core.²⁴ Assessing cellular levels of ER α by in-cell Western (ICW) assays (Figure 2A, Table 1) showed that only the Boc-Trp analog (4) had high, subnanomolar potency, although it was less efficacious than Fulvestrant; removal of the Boc group in 4 completely abolished its SERD activity (not shown). All three of the Boc-amino acid PROTACs were efficacious, low nanomolar inhibitors of MCF-7 cell proliferation (Table 1, Figure 3A), with the Boc-Phe and Boc-Trp analogs (3 and 4) being the most potent. Thus, the Boc group as well as the amino acid side chain make distinct contributions to the ER α degradation and antiproliferative activities.

Encouraged by the initial success of our new PROTAC model for ER, we sought to systematically investigate whether the ER degrading/antiproliferative capability depends on increased structural complexity/hydrophobicity of degron motifs in PROTACs. Thus, we prepared a series of bridged bicyclic and tricyclic analogs (5–10) and a variety of monocyclic analogs (11–15); with the adamantyl²⁶ candidate degron, and the length of the linker chain was also varied (5–7). The RBA values of most of these compounds were comparable to those of the previous series (1–4), with one (11) exceeding that of fulvestrant (1).

All members of the bi- and tricyclic group (5–10) were low nanomolar antiproliferative agents (Table 1, Figure 3B), with overall the three compounds having an adamantane degron (5–7) giving more complete suppression than those with other degron candidates (8–10). The length of the linker in compounds 5–7 had only a modest effect on antiproliferative potency and efficacy. Although the potencies of these compounds in degrading ER α were good, the extent of degradation varied (Table 1, Figure 2B), with compounds 6

Table 1. Structure–Activity Data of Novel SERDs: Summary of ER α Binding Affinity, Potency, and Efficacy in Antiproliferation and ER α Downregulation Assays^a

Entry	Structure (R)	RBA (estradiol = 100)	Antiproliferation IC ₅₀ (nM) [% of vehicle] ^b	ER α Down-regulation IC ₅₀ (nM) [% of vehicle] ^b
1	Fulvestrant	61 $\pm$ 1	<0.1 [0]	<0.1 [9]
Lipophilic amino acids as Degrons				
2		14 $\pm$ 1	36 [20]	636 [56]
3		14 $\pm$ 4	7 [25]	307 [71]
4		20 $\pm$ 6	16 [16]	0.5 [45]
Tricyclic and Bicyclic Degrons				
5	 (C2 linker, n=1)	21 $\pm$ 6	17 [16]	ND ^c [76]
6	 (C3 linker, n=2)	26 $\pm$ 6	9 [13]	3 [42]
7		11 $\pm$ 3	13 [13]	6 [51]
8		6.0 $\pm$ 0.1	5 [57]	10 [42]
Monocyclic Degrons				
9		17 $\pm$ 2	12 [42]	2 [71]
10		37 $\pm$ 0.3	9 [42]	0.5 [53]
Monocyclic Degrons				
11		70 $\pm$ 1	3 [15]	ND ^c [69]
12		28 $\pm$ 6	0.6 [13]	0.4 [35]
13		30 $\pm$ 5	5 [15]	ND ^c [76]
14		30 $\pm$ 0.1	4 [20]	ND ^c [67]
15		10 $\pm$ 0.4	0.5 [13]	2 [31]

^a $n = 3$, unless otherwise noted. ^bEfficacy values are expressed as % of ER α level (Figure 2) or relative proliferation rate (Figure 3) at the highest compound dose relative to vehicle control. Proliferation with Fulvestrant is considered zero. ^cIC₅₀ values could not be determined accurately due to limited ER α degradation.

and 8 being more complete than the others, and 5 being the least potent and efficacious.

As a group, the monocyclic compounds (11–15) proved to be more potent and complete as antiproliferative agents than the bridged polycyclic group (Table 1, Figure 3C), with compounds 12 and 15 having subnanomolar IC₅₀ values. This group was also more uniformly and fully efficacious, and all were as good as the best of the Boc-amino acids and bridged bi- and tricyclic series. Again, as ER α degraders (Table 1, Figure 2C), there were wider

variations, with 12 and 15 again having the most complete reduction of ER α levels. The turnover of ER was inhibited by proteasome inhibitor (MG132) (see Figure S1). Because the extent of degradation by compounds 11, 13, and 14 (as well as 5 from the bridged cyclic group) was modest, accurate IC₅₀ values could not be determined for these compounds.

It is notable that the above dose–response studies also suggest that the inhibitory activity of these PROTACs is not reduced at higher concentrations. The absence of this “hook effect” is an

Figure 2. Dose–response of ER α level in MCF-7 cells. MCF-7 cells in stripped medium were treated with indicated concentrations of Fulvestrant (1) or compounds 2–15 for 24 h, and ER α levels were determined by in-cell Western analysis. Values represent average $\pm$ SEM of four measurements. 100% represents ER α levels in vehicle treated samples (for representative Western blots, see SI, Figure S1).

important benefit of these novel PROTACs as compared to many of the current PROTACs that show reduced potency at higher concentrations.¹⁵ Overall, the compounds possessing degrons from N-end rule pathway (2–4) were less effective ER α degraders and antiproliferative agents as compared to those possessing bicyclic and monocyclic degrons (5–15). Further, the comparatively better potency of Fulvestrant could be due to its higher affinity (RBA = 61) toward the estrogen receptor compared to all of the new ligands but compound 11.

We selected for further characterization one compound of interest from each category, based on the structural novelty of the degron and a combination of their potency and efficacy in antiproliferative and ER α degradation assays: these were the Boc-Trp (4), the C3-linked adamantane (6), and particularly the trifluoromethyl cyclohexane (15). We assayed their activity as antagonists on three estrogen-regulated genes, progesterone receptor (PgR), pS2, and GREB1 (Figure 4). All of the compounds reduced the low control vehicle level of agonist activity (gray bars), and they all functioned as effective antagonists of ER α transcriptional regulation of these genes in the presence of E2 (stippled dark bars).

We have previously shown that the bisphenolic-adamantyl cores are high affinity ligands and partial agonists on ER α .²⁴ Therefore, the ER α degradation and antiproliferative and antagonist activities of our novel PROTACs are likely mediated mainly by the side chains (presumed to be degrons). Our data suggests that hydrophobicity of the degron, alone, is not a major driver of SERD or antiproliferative action of this new class of

Figure 3. Dose–response of MCF-7 cell proliferation. MCF-7 cells in complete medium were treated with indicated concentrations of Fulvestrant (1) or compounds 2–15 for 6 days, and cell densities were determined by MTT assays. Values represent average $\pm$ SEM of four measurements. 100% represents proliferation in vehicle treated samples.

SERDs. In fact, the degrons in the most potent compounds (4, 11, 12, and 15) had lower cLogP values (SI, Table S1) as compared to other degrons. The mechanism of action of our mono-Boc-protected amino acid degrons (2–4) also appears to be distinct from a recently described Boc₃Arg degron that requires all three Boc groups to be present on an arginine motif to retain its activity.²⁷ Crews et al. have done pioneering investigations of the adamantyl motif as a degron for androgen receptor and some other proteins.^{13,26} These studies suggest involvement of Heat Shock Proteins (Hsp 70 and 90) in the degradation pathway. Because Hsp 90 is also known to regulate folding/unfolding of ER,²⁸ this pathway might be playing a role in observed SERD behavior of some of our compounds (5–8). In addition, other factors such as enhanced cell permeability and/or induction of distinct destabilizing conformations of ER could also contribute to the increased potency of our compounds. In fact, the observation that some of our most potent antiproliferative agents (e.g., 12 and 15, possessing cyclohexyl degrons) were not complete ER α degraders (Table 1) suggests that these compounds could also be operating by inducing an antagonist conformation of ER α , a scenario previously shown in the case of Fulvestrant.²⁹ Although the precise mechanism of action of Fulvestrant is still unclear, previous studies suggest that the long alkyl chain of Fulvestrant interacts with a hydrophobic groove on ER that otherwise recruits ER coactivator proteins.³ Subsequently, two distinct

Figure 4. Assessment of selected compounds as antagonists of the expression of ER-regulated genes. MCF-7 cells were treated with 3 μ M of the indicated compounds or Fulvestrant, either alone or in the presence of 1 nM estradiol (E₂) for 24 h. Gene expression level was determined by qRT-PCR.

pathways operate: exposure of hydrophobic residues on ER and recruitment of corepressors to the hydrophobic groove.^{3,30}

Docking studies of our novel SERDs into ER α (SI, Figures S-2 and S-3) reveal that unlike Fulvestrant, the degons of our compounds are unable to fully occupy the coactivator groove due to the shorter linker lengths. After passing through an exit channel, the Boc-amino acid degons project in a direction opposite to that of tricyclic and monocyclic degons (Figure S-3C). Interestingly, the tricyclic/monocyclic degons are likely projected toward the loop connecting the helix-11 and -12 (Figures S-2 and S-3A,B). Collectively, the above results indicate likely involvement of novel and decoupled mechanisms for ER degradation and antagonism for our SERDs. Studies to elucidate more precisely the mechanism of action of these structurally distinct degons are currently underway.

In conclusion, this work represents a new addition to the very limited pool of distinct molecular scaffolds (Fulvestrant and GW type compounds) that are known to induce selective degradation of ER α and also antagonize ER α . Our molecular design strategy involved a PROTAC-based model, wherein a synthetically tractable ligand core was attached to various novel degon-type side chains in a highly modular fashion. Through these studies, we found members of three distinct degon classes (lipophilic amino acids, bridged cyclic systems, and simpler monocyclic systems) that had low nanomolar potencies as ER α degraders and antiproliferative agents that also inhibited ER target gene expression. The modular design, ease of synthesis

and ready availability of ligand cores and degons of this class of SERDs lay the foundation for rapid chemical diversification to optimize the ADMET properties, an area that has been a major bottleneck in clinical utility of SERDs. Beyond SERDs, this study also significantly expands the currently available toolbox for PROTACs, and these novel degons could be useful for the development of new PROTACs for targeted degradation of various other therapeutically relevant proteins.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmmedchemlett.8b00106.

Detailed experimental procedures for synthesis of compounds, characterization data for all compounds, cLogP data of degons, biological assay protocols, and molecular modeling data/method (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: abhishek.sharma@stevens.edu.

ORCID

John A. Katzenellenbogen: 0000-0003-0914-0010

Abhishek Sharma: 0000-0001-6070-4403

Author Contributions

[§]These authors contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank Dr. Athula Attygalle for HRMS analysis and Ye Zheng for assistance in some experiments. Financial support from Stevens Institute of Technology (to A.S.), the NIH (R01DK015556 to J.A.K.; predoctoral fellowship T32GM070421 to V.S.G.), NCI Cancer Center Support Grant (P30CA08748) to MSKCC, and the Breast Cancer Research Foundation (BCRF 17-083 to J.A.K. and B.S.K.; BCRF 17-082 to B.S.K.; BCRF 17-185 to S.C.) is gratefully acknowledged.

■ ABBREVIATIONS

ADMET, absorption, distribution, metabolism, excretion, toxicity; E₂, estradiol; ER, estrogen receptor; GREB1, growth regulation by estrogen in breast cancer 1; Hsp, heat shock protein; ICW, in-cell Western assay; LBP, ligand binding pocket; NHS, N-hydroxysuccinimide; PgR, progesterone receptor; PROTAC, proteolysis targeting chimera; RBA, relative binding affinity; SERD, selective estrogen receptor degrader

■ REFERENCES

- (1) Ariazi, E. A.; Ariazi, J. L.; Cordera, F.; Jordan, V. C. Estrogen receptors as therapeutic targets in breast cancer. *Curr. Top. Med. Chem.* **2006**, *6*, 181–202.
- (2) Toy, W.; Shen, Y.; Won, H.; Green, B.; Sakr, R. A.; Will, M.; Li, Z.; Gala, K.; Fanning, S.; King, T. A.; Hudis, C.; Chen, D.; Taran, T.; Hortobagyi, G.; Greene, G.; Berger, M.; Baselga, J.; Chandarlapaty, S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. *Nat. Genet.* **2013**, *45*, 1439–1445.

- (3) Pike, A. C.; Brzozowski, A. M.; Walton, J.; Hubbard, R. E.; Thorsell, A. G.; Li, Y. L.; Gustafsson, J. A.; Carlquist, M. Structural insights into the mode of action of a pure antiestrogen. *Structure* **2001**, *9*, 145–153.
- (4) Misawa, T.; Fujisato, T.; Kanda, Y.; Ohoka, N.; Shoda, T.; Yorioka, M.; Makishima, M.; Sekino, Y.; Naito, M.; Demizu, Y.; Kurihara, M. Design and synthesis of novel selective estrogen receptor degradation inducers based on the diphenylheptane skeleton. *MedChemComm* **2017**, *8*, 239–246.
- (5) Robertson, J. F. R. Fulvestrant (Faslodex®) – how to make a drug better. *Oncologist* **2007**, *12*, 774–784.
- (6) Willson, T. M.; Henke, B. R.; Momtahan, T. M.; Charifson, P. S.; Batchelor, K. W.; Lubahn, D. B.; Moore, L. B.; Oliver, B. B.; Sauls, H. R.; Triantafyllou, J. A.; Wolfe, S. G.; Baer, P. G. 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats. *J. Med. Chem.* **1994**, *37*, 1550–1552.
- (7) Lai, A.; Kahraman, M.; Govek, S.; Nagasawa, J.; Bonnefous, C.; Julien, J.; Douglas, K.; Sensintaffar, J.; Lu, N.; Lee, K. J.; Aparicio, A.; Kaufman, J.; Qian, J.; Shao, G.; Prudente, R.; Moon, M. J.; Joseph, J. D.; Darimont, B.; Brigham, D.; Grillo, K.; Heyman, R.; Rix, P. J.; Hager, J. H.; Smith, N. D. Identification of GDC-0810 (ARN-810), an orally bioavailable Selective Estrogen Receptor Degradator (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. *J. Med. Chem.* **2015**, *58*, 4888–4904.
- (8) De Savi, C.; Bradbury, R. H.; Rabow, A.; Norman, R. C.; de Almeida, C.; Andrews, D. M.; Ballard, P.; Buttar, D.; Callis, R. J.; Currie, G. S.; Curwen, J. O.; Davies, C. D.; Donald, C. S.; Feron, L. J.; Gingell, H.; Glossop, S. C.; Hayter, B. R.; Hussain, S.; Karoutchi, G.; Lamont, S. G.; MacFaul, P.; Moss, T. A.; Pearson, S. E.; Tonge, M.; Walker, G. E.; Weir, H. M.; Wilson, Z. Optimization of a novel binding motif to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable Selective Estrogen Receptor Downregulator and antagonist. *J. Med. Chem.* **2015**, *58*, 8128–8140.
- (9) Govek, S. P.; Nagasawa, J. Y.; Douglas, K. L.; Lai, A. G.; Kahraman, M.; Bonnefous, C.; Aparicio, A. M.; Darimont, B. D.; Grillo, K. L.; Joseph, J. D.; Kaufman, J. A.; Lee, K. J.; Lu, N.; Moon, M. J.; Prudente, R. Y.; Sensintaffar, J.; Rix, P. J.; Hager, J. H.; Smith, N. D. Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 5163–5167.
- (10) Weir, H. M.; Bradbury, R. H.; Lawson, M.; Rabow, A. A.; Buttar, D.; Callis, R. J.; Curwen, J. O.; de Almeida, C.; Ballard, P.; Hulse, M.; Donald, C. S.; Feron, L. J.; Karoutchi, G.; MacFaul, P.; Moss, T.; Norman, R. A.; Pearson, S. E.; Tonge, M.; Davies, G.; Walker, G. E.; Wilson, Z.; Rowlinson, R.; Powell, S.; Sadler, C.; Richmond, G.; Ladd, B.; Pazolli, E.; Mazzola, A. M.; D'Cruz, C.; De Savi, C. AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-Positive and ESR1-mutant breast tumors in preclinical models. *Cancer Res.* **2016**, *76*, 3307–3318.
- (11) For an interesting scaffold displaying mixed action (agonist/SERD), see: Wardell, S. E.; Nelson, E. R.; Chao, C. A.; Alley, H. M.; McDonnell, D. P. Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader. *Endocr.-Relat. Cancer* **2015**, *22*, 713–724.
- (12) Toure, M.; Crews, C. M. Small-molecule PROTACS: new approaches to protein degradation. *Angew. Chem., Int. Ed.* **2016**, *55*, 1966–1973.
- (13) Salami, J.; Crews, C. M. Waste disposal: an attractive strategy for cancer therapy. *Science* **2017**, *355*, 1163.
- (14) Winter, G. E.; Buckley, D. L.; Paulk, J.; Roberts, J. M.; Souza, A.; Paganon, S. D.; Bradner, J. E. Phthalimide conjugation as a strategy for in vivo target protein degradation. *Science* **2015**, *348*, 1376–1381.
- (15) Burslem, G. M.; Crews, C. M. Small-molecule modulation of protein homeostasis. *Chem. Rev.* **2017**, *117*, 11269–11301.
- (16) Lai, A. C.; Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm. *Nat. Rev. Drug Discovery* **2017**, *16*, 101–111.
- (17) Ottis, P.; Crews, C. M. Proteolysis-Targeting Chimeras: induced protein degradation as a therapeutic strategy. *ACS Chem. Biol.* **2017**, *12*, 892–898.
- (18) Itoh, Y.; Kitaguchi, R.; Ishikawa, M.; Naito, M.; Hashimoto, Y. Design, synthesis and biological evaluation of nuclear receptor-degradation inducers. *Bioorg. Med. Chem.* **2011**, *19*, 6768–6778.
- (19) Demizu, Y.; Okuhira, K.; Motoi, H.; Ohno, A.; Shoda, T.; Fukuhara, K.; Okuda, H.; Naito, M.; Kurihara, M. Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 1793–1796.
- (20) Jiang, Y.; Deng, Q.; Zhao, H.; Xie, M.; Chen, L.; Yin, F.; Qin, X.; Zheng, W.; Zhao, Y.; Li, Z. Development of stabilized peptide-based PROTACs against Estrogen Receptor α . *ACS Chem. Biol.* **2018**, *13*, 628–635.
- (21) Dougan, D. A.; Micevski, D.; Truscott, K. N. The N-end rule pathway: from recognition by N-recognins, to destruction by AAA+proteases. *Biochim. Biophys. Acta, Mol. Cell Res.* **2012**, *1823*, 83–91.
- (22) Min, J.; Guillen, V. S.; Sharma, A.; Zhao, Y.; Ziegler, Y.; Gong, P.; Mayne, C. G.; Srinivasan, S.; Kim, S. H.; Carlson, K. E.; Nettles, K. W.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Adamantyl antiestrogens with novel side chains reveal a spectrum of activities in suppressing estrogen receptor mediated activities in breast cancer cells. *J. Med. Chem.* **2017**, *60*, 6321–6336.
- (23) Zhao, Y.; Laws, M. J.; Guillen, V. S.; Ziegler, Y.; Min, J.; Sharma, A.; Kim, S. H.; Chu, D.; Park, B. H.; Oesterreich, S.; Mao, C.; Shapiro, D. J.; Nettles, K. W.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S. Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors. *Cancer Res.* **2017**, *77*, S602–S613.
- (24) Muthyala, R. S.; Sheng, S.; Carlson, K. E.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Bridged bicyclic cores containing a 1, 1-diarylethylene motif are high-affinity subtype-selective ligands for the estrogen receptor. *J. Med. Chem.* **2003**, *46*, 1589–1602.
- (25) Long, M. J. C.; Gollapalli, D. R.; Hedstrom, L. Inhibitor mediated protein degradation. *Chem. Biol.* **2012**, *19*, 629–637.
- (26) Gustafson, J. L.; Neklesa, T. K.; Cox, C. S.; Roth, A. G.; Buckley, D. L.; Tae, H. S.; Sundberg, T. B.; Stagg, D. B.; Hines, J.; McDonnell, D. P.; Norris, J. D.; Crews, C. M. Small-molecule-mediated degradation of the Androgen Receptor through hydrophobic tagging. *Angew. Chem., Int. Ed.* **2015**, *54*, 9659–9662.
- (27) Shi, Y.; Long, M. J. C.; Rosenberg, M. M.; Li, S.; Kobjack, A.; Lessans, P.; Coffey, R. T.; Hedstrom, L. Boc3Arg-linked ligands induce degradation by localizing target proteins to the 20S proteasome. *ACS Chem. Biol.* **2016**, *11*, 3328–3337.
- (28) Aumais, J. P.; Lee, H. S.; Lin, R.; White, J. H. Selective interaction of hsp90 with an estrogen receptor ligand-binding domain containing a point mutation. *J. Biol. Chem.* **1997**, *272*, 12229–12235.
- (29) Wardell, S. E.; Marks, J. R.; McDonnell, D. P. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. *Biochem. Pharmacol.* **2011**, *82*, 122–130.
- (30) Weatherman, R. V.; Clegg, N. J.; Scanlan, T. S. Differential SERM activation of the estrogen receptors (ER α and ER β) at AP-1 sites. *Chem. Biol.* **2001**, *8*, 427–436.